Acute lymphoblastic leukemia
Drug research and approvals for acute lymphoblastic leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 470 studies of acute lymphoblastic leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 45 drug trials for it since 2013, and FDA has 27 approved and 47 open orphan designations naming it.
- Recruiting worldwide: 470
- Trials authorized in Canada: 45
- FDA orphan approvals: 27
- EU medicines: 0
Recruiting Now
Newest start dates first, of 470 recruiting on ClinicalTrials.gov ↗- Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic…NCT07758673 · Phase 1 · City of Hope Medical Center · starts Apr 17, 2027
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute…NCT07936266 · Phase 1 · Sunil G. Iyer · starts Mar 31, 2027
- A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed,…NCT07614022 · Phase 1 · Wake Forest University Health Sciences · starts Dec 1, 2026
- Feasibility and Acceptability of Remote Saliva CollectionNCT07884474 · Not reported · St. Jude Children's Research Hospital · starts Dec 1, 2026
- BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic LeukemiaNCT07854652 · Phase 1 · The First Affiliated Hospital of Soochow University · starts Dec 1, 2026
- Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory…NCT07572136 · Phase 1 · National Cancer Institute (NCI) · starts Nov 19, 2026
- A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide…NCT05621291 · Not applicable · National Cancer Institute (NCI) · starts Nov 19, 2026
- Impact of Vitamin D on Gut Microbiome and Metabolome Among Pediatric Oncology PatientsNCT07938333 · Not reported · Children's Hospital of Orange County · starts Nov 9, 2026
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients…NCT06904066 · Phase 1 · National Cancer Institute (NCI) · starts Oct 28, 2026
- Prophylactic DLI-X for Leukemia Relapse After HCTNCT07254793 · Phase 1 · University of Arizona · starts Oct 26, 2026
Trials Authorized in Canada
The 10 newest of 45; search them all in Canada trials| Sep 25, 2026 | A phase 1/2, dose optimization and dose expansion, multicenter, open-label study to evaluate the safety, pharmacokinetics, and efficacy of menin inhibitor…VICRIMENIB (S243249, BN104) | Servier | Pending |
| May 28, 2026 | Open label dose-escalation and dose expansion study to evaluate the safety, expansion, persistence and clinical activity of ucart22 {allogeneic engineered…UCART22 / CLLS52 | CELLECTIS S.A. | Closed |
| Apr 15, 2026 | A phase 2/3, randomized, open-label, comparison study of mk-1045 versus blinatumomab in participants with relapsed or refractory cd 19+ b-cell acute…MK-1045 | Merck & Co. (MSD) | Ongoing |
| Apr 1, 2026 | A global multicenter, open label, randomized phase 3 registrational study of olverembatinib combined with hemotherapy versus investigator’s choice of tki…OLVEREMBATINIB / IMATINIB / DASATINIB / PONATINIB | ASCENTAGE PHARMA GROUP INC. | Pending |
| Dec 23, 2025 | Phase II study of subcutaneous blinatumomab plus ponatinib for bcr-abl positive b-cell acute lymphoblastic leukemiaBLINCYTO / ICLUSIG | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA | Pending |
| Nov 27, 2025 | A phase 3, open-label, randomized, controlled trial of subcutaneous versus intravenous blinatumomab in newly diagnosed adults with philadelphia chromosome…SUBCUTANEOUS (SC) BLINATUMOMAB / RITUXIMAB | Amgen | Pending |
| Sep 12, 2025 | A modular phase I/ii, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of…AZD4512 | AstraZeneca Pharmaceuticals LP | Ongoing |
| Sep 5, 2025 | A phase 1b/2 study to investigate the safety, efficacy and pharmacokinetics of administration of subcutaneous (sc) blinatumomab in pediatric participants with…BLINCYTO | Amgen | Pending |
| Aug 26, 2025 | Total therapy for infants with acute lymphoblastic leukemia iiZIFTOMENIB / BLINATUMOMAB / VORINOSTAT / BORTEZOMIB | PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTIC INVESTIGATOR CONSORTIUM | Pending |
| Aug 14, 2025 | An international pilot study of chemotherapy and tyrosine kinase inhibitors with blinatumomab in patients with newly-diognosed philadelphia chromosome-positive…BLINCYTO | CHILDRENS ONCOLOGY GROUP | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 74| Aug 1, 2025 | Phyragotreatment of pediatric patients 1 year of age and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia… | Handa Therapeutics, LLC | Approved |
| Nov 8, 2024 | Aucatzyltreatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) | Autolus Incorporated, US subsidiary of Autolus Limited | Approved |
| Jun 14, 2024 | Blincytotreatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase… | Amgen, Inc. | Approved |
| Mar 19, 2024 | Iclusigtreatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination… | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Mar 6, 2024 | Besponsatreatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1… | Wyeth Pharmaceuticals, LLC | Approved |
| Dec 5, 2023 | Phyragotreatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to… | Handa Therapeutics, LLC | Approved |
| Oct 1, 2021 | TecartusTreatment of adult patients with relapsed or refractory B-cell precursor acute lymphomblastic leukemia (ALL) | Kite Pharma, Inc. | Approved |
| Jun 30, 2021 | RylazeAs a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma… | Jazz Pharmaceuticals Ireland Limited | Approved |
| Dec 21, 2018 | SprycelSPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in… | Bristol-Myers Squibb Company | Approved |
| Dec 20, 2018 | Oncaspar; AsparlasASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in… | Servier Pharmaceuticals LLC | Approved |
| Mar 29, 2018 | BlincytoBLINCYTO® is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with… | Amgen, Inc. | Approved |
| Aug 30, 2017 | Kymriah (tisagenlecleucel)Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or… | Novartis Pharmaceuticals Corporation | Approved |
| Aug 17, 2017 | inotuzumab ozogamicinTreatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) | Wyeth Pharmaceuticals, LLC | Approved |
| Jul 11, 2017 | Blincytotreatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children | Amgen, Inc. | Approved |
| Apr 25, 2017 | XatmepTreatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen | Silvergate Pharmaceuticals, Inc. | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA